Because of the rising variety of therapeutic monoclonal antibodies (mAbs) used within the clinic, there’s an rising want for sturdy analytical strategies to quantify complete mAb concentrations in human plasma for medical research and therapeutic drug monitoring.
We developed a simple, fast, and sturdy pattern preparation methodology for liquid chromatography-tandem mass spectrometry (LC-MS/MS) evaluation. The tactic was validated for infliximab (IFX), rituximab (RTX), cetuximab (CTX), dupilumab (DPL), dinutuximab (DNX), vedolizumab (VDZ), and emicizumab (EMZ). Saturated ammonium sulfate (AS) was used to precipitate immunoglobulins in human plasma.
After centrifugation, supernatant containing albumin was decanted, and the precipitated immunoglobulin fraction was re-dissolved in buffer containing 6M guanidine. This fraction was then utterly denatured, lowered, alkylated, and trypsin digested. Lastly, signature peptides from the seven mAbs had been concurrently quantified on LC-MS/MS along with their inside requirements secure isotopically labeled peptide counterparts.
The linear dynamic ranges (1 – 512 mg/L) of IFX, CTX, RTX, and EMZ confirmed wonderful (R2 > 0.999) linearity and people of DPL, DNX, and VDZ confirmed good (R2 > 0.995) linearity. The tactic was validated in accordance with the EMA tips. EDTA plasma, sodium citrate plasma, heparin plasma, and serum yielded comparable outcomes.
Ready samples had been secure at room temperature (20°C) and at 5°C for three days, and confirmed no decline in focus for all examined mAbs. This described methodology, which has the benefit of a simple, fast, and sturdy pre-analytical pattern preparation, can be utilized as a template to quantify different mAbs in human plasma or serum.
Reactions and COVID-19 illness development following SARS-CoV-2 monoclonal antibody infusion
SARS-CoV-2 monoclonal antibodies (mAbs) have been proposed as a remedy for gentle to average COVID-19, with favorable outcomes reported in medical trials and an emergency use authorization granted by the Meals and Drug Administration. Actual-world knowledge stay restricted, nevertheless, and thus this evaluation presents findings from over 6,500 outpatient administrations of mAb at services affiliated with a big healthcare group in the US.
Inside 48 hours of mAb infusion, 15.6% (1,043) of sufferers obtained a drug that was indicative of a potential response to the infusion; the vast majority of these had been gentle (e.g., acetaminophen). Roughly 5.2% of sufferers who obtained mAb (n=347) had a post-infusion emergency division go to or admission for COVID-19 illness development.
The outcomes of this evaluation point out that sufferers who obtain mAb have a low chance of each an instantaneous detrimental response to the remedy in addition to future inpatient admission associated to COVID-19 illness development.
A SARS-CoV-2 antibody broadly neutralizes SARS-related coronaviruses and variants by coordinated recognition of a virus-vulnerable web site
Potent neutralizing SARS-CoV-2 antibodies typically goal the spike protein receptor-binding web site (RBS), however the variability of RBS epitopes hampers broad neutralization of a number of sarbecoviruses and drifted viruses. Right here, utilizing humanized mice, we recognized an RBS antibody with a germline VH gene that potently neutralized SARS-related coronaviruses, together with SARS-CoV and SARS-CoV-2 variants.
X-ray crystallography revealed coordinated recognition by the heavy chain of non-RBS conserved websites and the sunshine chain of RBS with a binding angle mimicking the angiotensin-converting enzyme 2 (ACE2) receptor. The minimal footprints within the hypervariable area of RBS contributed to the breadth of neutralization, which was enhanced by immunoglobulin G3 (IgG3) class switching.
The coordinated binding resulted in broad neutralization of SARS-CoV and rising SARS-CoV-2 variants of concern. Low-dose therapeutic antibody remedy in hamsters lowered the virus titers and morbidity throughout SARS-CoV-2 problem. The structural foundation for broad neutralizing exercise could inform the design of a broad spectrum of therapeutics and vaccines.
Pharmacodynamic measures inside tumors expose differential exercise of PD(L)-1 antibody therapeutics
Macromolecules reminiscent of monoclonal antibodies (mAbs) are prone to expertise poor tumor penetration due to their massive dimension, and thus low drug publicity of goal cells inside a tumor might contribute to suboptimal responses. Given the problem of insufficient quantitative instruments to evaluate mAb exercise inside tumors, we hypothesized that measurement of accessible goal ranges in tumors might elucidate the pharmacologic exercise of a mAb and might be used to match the exercise of various mAbs.
Utilizing positron emission tomography (PET), we measured the pharmacodynamics of immune checkpoint protein programmed-death ligand 1 (PD-L1) to guage pharmacologic results of mAbs concentrating on PD-L1 and its receptor programmed cell demise protein 1 (PD-1). For PD-L1 quantification, we first developed a small peptide-based fluorine-18-labeled PET imaging agent, [18F]DK222, which supplied high-contrast pictures in preclinical fashions.
We then quantified accessible PD-L1 ranges within the tumor mattress throughout remedy with anti-PD-1 and anti-PD-L1 mAbs. Making use of mixed-effects fashions to those knowledge, we discovered delicate variations within the pharmacodynamic results of two anti-PD-1 mAbs (nivolumab and pembrolizumab).
In distinction, we noticed starkly divergent goal engagement with anti-PD-L1 mAbs (atezolizumab, avelumab, and durvalumab) that had been administered at equal doses, correlating with differential results on tumor development. Thus, we present that measuring PD-L1 pharmacodynamics informs mechanistic understanding of therapeutic mAbs concentrating on PD-L1 and PD-1.
These findings exhibit the worth of quantifying goal pharmacodynamics to elucidate the pharmacologic exercise of mAbs, unbiased of mAb biophysical properties and inclusive of all physiological variables, that are extremely heterogeneous inside and throughout tumors and sufferers.
Ehrlichia chaffeensis and E. canis hypothetical protein immunoanalysis reveals small secreted immunodominant proteins and conformation-dependent antibody epitopes
Immunomolecular characterization of Ehrlichia chaffeensis (E. ch.) and E. canis (E. ca.) has outlined protein orthologs, together with tandem repeat proteins (TRPs) which have immunodominant linear antibody epitopes. On this examine, we mixed bioinformatic evaluation and cell-free protein expression to determine undiscovered immunoreactive E. ch. and E. ca. hypothetical proteins.
Antigenicity of the E. ch. and E. ca. ORFeomes (n = 1105 and n = 925, respectively) was analyzed by the sequence-based prediction mannequin ANTIGENpro, and we recognized ~250 ORFs in every respective ORFeome as extremely antigenic. The hypothetical proteins (E. ch. n = 93 and E. ca. n = 98) current within the prime 250 antigenic ORFs had been additional investigated on this examine. By ELISA, 46 E. ch. and 30 E. ca.
IVTT-expressed hypothetical proteins reacted with antibodies in sera from naturally E. ch.-infected sufferers or E. ca.-infected canine. Furthermore, 15 E. ch. and 16 E. ca. proteins persistently reacted with a panel of sera from sufferers or canine, together with many that exposed the immunoreactivity of “gold commonplace” TRPs. Antibody epitopes in most (>70%) of those proteins exhibited partial or full conformation-dependence.
 Antibody) Cytokeratin 14 (Cytokeratin 14) Antibody |
|
20-abx009056 |
Abbexa |
-
EUR 300.00
-
EUR 439.00
-
EUR 189.00
|
|
|
|
 Antibody) Cytokeratin 8 (Cytokeratin 8) Antibody |
|
20-abx009059 |
Abbexa |
-
EUR 300.00
-
EUR 439.00
-
EUR 189.00
|
|
|
|
 Antibody) Cytokeratin 7 (Cytokeratin 7) Antibody |
|
20-abx009060 |
Abbexa |
-
EUR 300.00
-
EUR 439.00
-
EUR 189.00
|
|
|
|
 Antibody) Cytokeratin 15 (Cytokeratin 15) Antibody |
|
20-abx225265 |
Abbexa |
-
EUR 370.00
-
EUR 606.00
-
EUR 314.00
|
|
|
|
Cytokeratin 14 (Cytokeratin 14) Antibody |
|
abx232195-100ug |
Abbexa |
100 ug |
EUR 481 |
|
|
Cytokeratin 14 (Cytokeratin 14) Antibody |
|
abx232196-100ug |
Abbexa |
100 ug |
EUR 509 |
|
|
Cytokeratin 14 (Cytokeratin 14) Antibody |
|
abx232197-100ug |
Abbexa |
100 ug |
EUR 551 |
|
|
Cytokeratin 15 (Cytokeratin 15) Antibody |
|
abx232198-100ug |
Abbexa |
100 ug |
EUR 481 |
|
|
Cytokeratin 15 (Cytokeratin 15) Antibody |
|
abx232199-100ug |
Abbexa |
100 ug |
EUR 509 |
|
|
 Antibody) Cytokeratin 4 (Cytokeratin 4) Antibody |
|
abx232214-100ug |
Abbexa |
100 ug |
EUR 481 |
|
|
Cytokeratin 7 (Cytokeratin 7) Antibody |
|
abx232217-100ug |
Abbexa |
100 ug |
EUR 509 |
|
|
Cytokeratin 7 (Cytokeratin 7) Antibody |
|
abx232218-100ug |
Abbexa |
100 ug |
EUR 551 |
|
|
Cytokeratin 8 (Cytokeratin 8) Antibody |
|
abx232221-100ug |
Abbexa |
100 ug |
EUR 481 |
|
|
Cytokeratin 8 (Cytokeratin 8) Antibody |
|
abx232222-100ug |
Abbexa |
100 ug |
EUR 551 |
|
|
Cytokeratin 8 (Cytokeratin 8) Antibody |
|
abx232223-100ug |
Abbexa |
100 ug |
EUR 551 |
|
|
Cytokeratin 8 (Cytokeratin 8) Antibody |
|
abx139677-01mg |
Abbexa |
0.1 mg |
EUR 356 |
|
|
Cytokeratin 8 (Cytokeratin 8) Antibody |
|
abx139678-01mg |
Abbexa |
0.1 mg |
EUR 356 |
|
|
 Antibody (FITC)) Cytokeratin 8 (Cytokeratin 8) Antibody (FITC) |
|
abx139679-01mg |
Abbexa |
0.1 mg |
EUR 425 |
|
|
 Cytokeratin antibody |
|
20R-CP006 |
Fitzgerald |
100 uL |
EUR 459 |
|
Description: Guinea Pig polyclonal Cytokeratin antibody |
Cytokeratin antibody |
|
10R-6655 |
Fitzgerald |
100 ug |
EUR 521 |
|
Description: Mouse monoclonal Cytokeratin antibody |
Cytokeratin antibody |
|
10R-6656 |
Fitzgerald |
100 ug |
EUR 521 |
|
Description: Mouse monoclonal Cytokeratin antibody |
 Cytokeratin 5 antibody |
|
70R-35563 |
Fitzgerald |
100 ug |
EUR 349 |
|
Description: Purified Rabbit polyclonal Cytokeratin 5 antibody |
 Cytokeratin 1 antibody |
|
70R-4604 |
Fitzgerald |
50 ug |
EUR 467 |
|
Description: Rabbit polyclonal Cytokeratin 1 antibody |
Cytokeratin 5 antibody |
|
70R-49975 |
Fitzgerald |
100 ul |
EUR 244 |
|
Description: Purified Polyclonal Cytokeratin 5 antibody |
 Cytokeratin 7 antibody |
|
70R-49976 |
Fitzgerald |
100 ul |
EUR 244 |
|
Description: Purified Polyclonal Cytokeratin 7 antibody |
 Cytokeratin 8 antibody |
|
70R-49977 |
Fitzgerald |
100 ul |
EUR 287 |
|
Description: Purified Polyclonal Cytokeratin 8 antibody |
Cytokeratin 8 antibody |
|
70R-49978 |
Fitzgerald |
100 ul |
EUR 244 |
|
Description: Purified Polyclonal Cytokeratin 8 antibody |
 Cytokeratin 10 antibody |
|
70R-49979 |
Fitzgerald |
100 ul |
EUR 244 |
|
Description: Purified Polyclonal Cytokeratin 10 antibody |
 Cytokeratin 13 antibody |
|
70R-49980 |
Fitzgerald |
100 ul |
EUR 244 |
|
Description: Purified Polyclonal Cytokeratin 13 antibody |
 Cytokeratin 14 antibody |
|
70R-49981 |
Fitzgerald |
100 ul |
EUR 244 |
|
Description: Purified Polyclonal Cytokeratin 14 antibody |
 Cytokeratin 16 antibody |
|
70R-49982 |
Fitzgerald |
100 ul |
EUR 244 |
|
Description: Purified Polyclonal Cytokeratin 16 antibody |
 Cytokeratin 17 antibody |
|
70R-49983 |
Fitzgerald |
100 ul |
EUR 244 |
|
Description: Purified Polyclonal Cytokeratin 17 antibody |
 Cytokeratin 18 antibody |
|
70R-49984 |
Fitzgerald |
100 ul |
EUR 287 |
|
Description: Purified Polyclonal Cytokeratin 18 antibody |
Cytokeratin 18 antibody |
|
70R-49985 |
Fitzgerald |
100 ul |
EUR 244 |
|
Description: Purified Polyclonal Cytokeratin 18 antibody |
 Cytokeratin 19 antibody |
|
70R-49986 |
Fitzgerald |
100 ul |
EUR 244 |
|
Description: Purified Polyclonal Cytokeratin 19 antibody |
Cytokeratin 19 antibody |
|
70R-49987 |
Fitzgerald |
100 ul |
EUR 244 |
|
Description: Purified Polyclonal Cytokeratin 19 antibody |
 Cytokeratin 84 antibody |
|
70R-49988 |
Fitzgerald |
100 ul |
EUR 244 |
|
Description: Purified Polyclonal Cytokeratin 84 antibody |
Cytokeratin 8 antibody |
|
70R-51570 |
Fitzgerald |
100 ul |
EUR 244 |
|
Description: Purified Polyclonal Cytokeratin 8 antibody |
Cytokeratin 8 antibody |
|
70R-51571 |
Fitzgerald |
100 ul |
EUR 244 |
|
Description: Purified Polyclonal Cytokeratin 8 antibody |
Cytokeratin 18 antibody |
|
70R-51572 |
Fitzgerald |
100 ul |
EUR 287 |
|
Description: Purified Polyclonal Cytokeratin 18 antibody |
Cytokeratin 18 antibody |
|
70R-51573 |
Fitzgerald |
100 ul |
EUR 244 |
|
Description: Purified Polyclonal Cytokeratin 18 antibody |
Cytokeratin 17 antibody |
|
70R-3229 |
Fitzgerald |
50 ug |
EUR 467 |
|
Description: Rabbit polyclonal Cytokeratin 17 antibody raised against the C terminal of KRT17 |
Cytokeratin 8 antibody |
|
70R-3263 |
Fitzgerald |
50 ug |
EUR 467 |
|
Description: Rabbit polyclonal Cytokeratin 8 antibody raised against the middle region of KRT8 |
Cytokeratin 8 antibody |
|
70R-3292 |
Fitzgerald |
50 ug |
EUR 467 |
|
Description: Rabbit polyclonal Cytokeratin 8 antibody raised against the N terminal of KRT8 |
Cytokeratin 18 antibody |
|
70R-33530 |
Fitzgerald |
100 ug |
EUR 327 |
|
Description: Rabbit polyclonal Cytokeratin 18 antibody |
Cytokeratin 8 antibody |
|
70R-33532 |
Fitzgerald |
100 ug |
EUR 327 |
|
Description: Rabbit polyclonal Cytokeratin 8 antibody |
 Cytokeratin 13 Antibody |
|
AF5102 |
Affbiotech |
200ul |
EUR 304 |
|
Description: Cytokeratin 13 Antibody detects endogenous levels of total Cytokeratin 13. |
 Cytokeratin 19 Antibody |
|
AF5106 |
Affbiotech |
200ul |
EUR 304 |
|
Description: Cytokeratin 19 Antibody detects endogenous levels of total Cytokeratin 19. |
 Cytokeratin 5 Antibody |
|
BF0108 |
Affbiotech |
200ul |
EUR 376 |
|
Description: Cytokeratin 5 antibody detects endogenous levels of total Cytokeratin 5. |
Cytokeratin 19 Antibody |
|
BF0197 |
Affbiotech |
200ul |
EUR 376 |
|
Description: Cytokeratin 19 antibody detects endogenous levels of total Cytokeratin 19. |
 Cytokeratin 8 Antibody |
|
BF0606 |
Affbiotech |
200ul |
EUR 376 |
|
Description: Cytokeratin 8 antibody detects endogenous levels of total Cytokeratin 8. |
Cytokeratin 18 antibody |
|
BF0727 |
Affbiotech |
200ul |
EUR 376 |
|
Description: Cytokeratin 18 mouse monoclonal antibody detects endogenous levels of total CK18. |
 anti-Cytokeratin 4 |
|
YF-PA12870 |
Abfrontier |
50 ul |
EUR 363 |
|
Description: Mouse polyclonal to Cytokeratin 4 |
anti-Cytokeratin 4 |
|
YF-PA12871 |
Abfrontier |
100 ug |
EUR 403 |
|
Description: Rabbit polyclonal to Cytokeratin 4 |
 anti-Cytokeratin 5 |
|
YF-PA12872 |
Abfrontier |
100 ug |
EUR 403 |
|
Description: Rabbit polyclonal to Cytokeratin 5 |
 anti-Cytokeratin 7 |
|
YF-PA12874 |
Abfrontier |
50 ug |
EUR 363 |
|
Description: Mouse polyclonal to Cytokeratin 7 |
anti-Cytokeratin 7 |
|
YF-PA12875 |
Abfrontier |
100 ug |
EUR 403 |
|
Description: Rabbit polyclonal to Cytokeratin 7 |
 anti-Cytokeratin 8 |
|
YF-PA12876 |
Abfrontier |
50 ul |
EUR 363 |
|
Description: Mouse polyclonal to Cytokeratin 8 |
anti-Cytokeratin 8 |
|
YF-PA12877 |
Abfrontier |
50 ug |
EUR 363 |
|
Description: Mouse polyclonal to Cytokeratin 8 |
anti-Cytokeratin 8 |
|
YF-PA12878 |
Abfrontier |
50 ul |
EUR 363 |
|
Description: Mouse polyclonal to Cytokeratin 8 |
anti-Cytokeratin 8 |
|
YF-PA12879 |
Abfrontier |
50 ug |
EUR 363 |
|
Description: Mouse polyclonal to Cytokeratin 8 |
anti-Cytokeratin 8 |
|
YF-PA12880 |
Abfrontier |
100 ul |
EUR 403 |
|
Description: Rabbit polyclonal to Cytokeratin 8 |
anti-Cytokeratin 8 |
|
YF-PA12881 |
Abfrontier |
100 ug |
EUR 403 |
|
Description: Rabbit polyclonal to Cytokeratin 8 |
 anti-Cytokeratin 14 |
|
YF-PA12883 |
Abfrontier |
50 ug |
EUR 363 |
|
Description: Mouse polyclonal to Cytokeratin 14 |
anti-Cytokeratin 14 |
|
YF-PA12884 |
Abfrontier |
100 ug |
EUR 403 |
|
Description: Rabbit polyclonal to Cytokeratin 14 |
 anti-Cytokeratin 15 |
|
YF-PA12886 |
Abfrontier |
100 ul |
EUR 403 |
|
Description: Rabbit polyclonal to Cytokeratin 15 |
anti-Cytokeratin 15 |
|
YF-PA12887 |
Abfrontier |
100 ug |
EUR 403 |
|
Description: Rabbit polyclonal to Cytokeratin 15 |
 anti-Cytokeratin 16 |
|
YF-PA12888 |
Abfrontier |
50 ul |
EUR 363 |
|
Description: Mouse polyclonal to Cytokeratin 16 |
anti-Cytokeratin 16 |
|
YF-PA12889 |
Abfrontier |
100 ug |
EUR 403 |
|
Description: Rabbit polyclonal to Cytokeratin 16 |
 anti-Cytokeratin 17 |
|
YF-PA12890 |
Abfrontier |
50 ul |
EUR 363 |
|
Description: Mouse polyclonal to Cytokeratin 17 |
anti-Cytokeratin 17 |
|
YF-PA12891 |
Abfrontier |
100 ug |
EUR 403 |
|
Description: Rabbit polyclonal to Cytokeratin 17 |
 anti-Cytokeratin 18 |
|
YF-PA12892 |
Abfrontier |
50 ul |
EUR 363 |
|
Description: Mouse polyclonal to Cytokeratin 18 |
anti-Cytokeratin 18 |
|
YF-PA12893 |
Abfrontier |
100 ug |
EUR 403 |
|
Description: Rabbit polyclonal to Cytokeratin 18 |
 anti-Cytokeratin 19 |
|
YF-PA12894 |
Abfrontier |
50 ug |
EUR 363 |
|
Description: Mouse polyclonal to Cytokeratin 19 |
anti-Cytokeratin 19 |
|
YF-PA12895 |
Abfrontier |
50 ug |
EUR 363 |
|
Description: Mouse polyclonal to Cytokeratin 19 |
anti-Cytokeratin 19 |
|
YF-PA12896 |
Abfrontier |
100 ug |
EUR 403 |
|
Description: Rabbit polyclonal to Cytokeratin 19 |
 anti-Cytokeratin 34 |
|
YF-PA12899 |
Abfrontier |
50 ug |
EUR 363 |
|
Description: Mouse polyclonal to Cytokeratin 34 |
anti-Cytokeratin 34 |
|
YF-PA12900 |
Abfrontier |
100 ul |
EUR 403 |
|
Description: Rabbit polyclonal to Cytokeratin 34 |
anti-Cytokeratin 34 |
|
YF-PA12901 |
Abfrontier |
100 ug |
EUR 403 |
|
Description: Rabbit polyclonal to Cytokeratin 34 |
 anti-Cytokeratin 2 |
|
YF-PA18999 |
Abfrontier |
50 ul |
EUR 363 |
|
Description: Mouse polyclonal to Cytokeratin 2 |
anti-Cytokeratin 2 |
|
YF-PA19000 |
Abfrontier |
50 ug |
EUR 363 |
|
Description: Mouse polyclonal to Cytokeratin 2 |
 anti-Cytokeratin 20 |
|
YF-PA19307 |
Abfrontier |
50 ul |
EUR 363 |
|
Description: Mouse polyclonal to Cytokeratin 20 |
anti-Cytokeratin 20 |
|
YF-PA19308 |
Abfrontier |
50 ug |
EUR 363 |
|
Description: Mouse polyclonal to Cytokeratin 20 |
anti-Cytokeratin 20 |
|
YF-PA19309 |
Abfrontier |
100 ul |
EUR 403 |
|
Description: Rabbit polyclonal to Cytokeratin 20 |
anti-Cytokeratin 20 |
|
YF-PA19310 |
Abfrontier |
100 ug |
EUR 403 |
|
Description: Rabbit polyclonal to Cytokeratin 20 |
anti-Cytokeratin 4 |
|
YF-PA24059 |
Abfrontier |
50 ul |
EUR 334 |
|
Description: Mouse polyclonal to Cytokeratin 4 |
anti-Cytokeratin 8 |
|
YF-PA24060 |
Abfrontier |
50 ul |
EUR 334 |
|
Description: Mouse polyclonal to Cytokeratin 8 |
anti-Cytokeratin 16 |
|
YF-PA24061 |
Abfrontier |
50 ul |
EUR 334 |
|
Description: Mouse polyclonal to Cytokeratin 16 |
anti-Cytokeratin 18 |
|
YF-PA24062 |
Abfrontier |
50 ul |
EUR 334 |
|
Description: Mouse polyclonal to Cytokeratin 18 |
anti-Cytokeratin 18 |
|
YF-PA25730 |
Abfrontier |
50 ul |
EUR 334 |
|
Description: Mouse polyclonal to Cytokeratin 18 |
 Cytokeratin 18 protein |
|
30R-AC039 |
Fitzgerald |
250 ug |
EUR 681 |
|
Description: Purified recombinant Human Cytokeratin 18 protein |
 Cytokeratin 19 protein |
|
30R-AC040 |
Fitzgerald |
100 ug |
EUR 413 |
|
Description: Purified recombinant Human Cytokeratin 19 protein |
 Cytokeratin 8 protein |
|
30R-AC041 |
Fitzgerald |
100 ug |
EUR 418 |
|
Description: Purified recombinant Human Cytokeratin 8 protein |
Cytokeratin 14 antibody |
|
20R-CP002 |
Fitzgerald |
100 ul |
EUR 564 |
|
Description: Guinea Pig polyclonal Cytokeratin 14 antibody |
Cytokeratin 5 antibody |
|
20R-CP003 |
Fitzgerald |
100 uL |
EUR 545 |
|
Description: Guinea Pig polyclonal Cytokeratin 5 antibody |
Cytokeratin 13 antibody |
|
70R-1178 |
Fitzgerald |
100 ug |
EUR 377 |
|
Description: Rabbit polyclonal Cytokeratin 13 antibody raised against the C terminal of KRT13 |
 Cytokeratin 20 antibody |
|
70R-1189 |
Fitzgerald |
100 ug |
EUR 377 |
|
Description: Rabbit polyclonal Cytokeratin 20 antibody raised against the middle region of KRT20 |
 Cytokeratin 2 antibody |
|
70R-12684 |
Fitzgerald |
100 ul |
EUR 457 |
|
Description: Affinity purified Rabbit polyclonal Cytokeratin 2 antibody |
Cytokeratin 10 antibody |
|
70R-13235 |
Fitzgerald |
100 ul |
EUR 430 |
|
Description: Affinity purified Rabbit polyclonal Cytokeratin 10 antibody |
Cytokeratin 13 antibody |
|
70R-13317 |
Fitzgerald |
100 ul |
EUR 457 |
|
Description: Affinity purified Rabbit polyclonal Cytokeratin 13 antibody |
Cytokeratin 20 antibody |
|
70R-13379 |
Fitzgerald |
100 ul |
EUR 457 |
|
Description: Affinity purified Rabbit polyclonal Cytokeratin 20 antibody |
 Cytokeratin 34 antibody |
|
70R-13483 |
Fitzgerald |
100 ul |
EUR 457 |
|
Description: Affinity purified Rabbit polyclonal Cytokeratin 34 antibody |
 Cytokeratin 31 antibody |
|
70R-13495 |
Fitzgerald |
100 ul |
EUR 457 |
|
Description: Affinity purified Rabbit polyclonal Cytokeratin 31 antibody |
Cytokeratin 10 antibody |
|
70R-2225 |
Fitzgerald |
50 ug |
EUR 467 |
|
Description: Rabbit polyclonal Cytokeratin 10 antibody |
Cytokeratin 13 antibody |
|
70R-2265 |
Fitzgerald |
50 ug |
EUR 467 |
|
Description: Rabbit polyclonal Cytokeratin 13 antibody raised against the N terminal of KRT13 |
Cytokeratin 16 antibody |
|
70R-2869 |
Fitzgerald |
50 ug |
EUR 467 |
|
Description: Rabbit polyclonal Cytokeratin 16 antibody |
Cytokeratin 16 antibody |
|
70R-2870 |
Fitzgerald |
50 ug |
EUR 467 |
|
Description: Rabbit polyclonal Cytokeratin 16 antibody |
Cytokeratin 7 antibody |
|
70R-2930 |
Fitzgerald |
50 ug |
EUR 467 |
|
Description: Rabbit polyclonal Cytokeratin 7 antibody raised against the N terminal of KRT7 |
Cytokeratin 19 antibody |
|
70R-2947 |
Fitzgerald |
50 ug |
EUR 467 |
|
Description: Rabbit polyclonal Cytokeratin 19 antibody raised against the N terminal of KRT19 |
 Cytokeratin 23 antibody |
|
70R-2948 |
Fitzgerald |
50 ug |
EUR 467 |
|
Description: Rabbit polyclonal Cytokeratin 23 antibody |
 Cytokeratin 24 antibody |
|
70R-2986 |
Fitzgerald |
50 ug |
EUR 467 |
|
Description: Rabbit polyclonal Cytokeratin 24 antibody raised against the middle region of KRT24 |
Cytokeratin 84 antibody |
|
70R-3002 |
Fitzgerald |
50 ug |
EUR 467 |
|
Description: Rabbit polyclonal Cytokeratin 84 antibody raised against the middle region of KRT84 |
Cytokeratin 19 antibody |
|
70R-3035 |
Fitzgerald |
50 ug |
EUR 467 |
|
Description: Rabbit polyclonal Cytokeratin 19 antibody raised against the N terminal of KRT19 |
 Cytokeratin 75 antibody |
|
70R-3038 |
Fitzgerald |
50 ug |
EUR 467 |
|
Description: Rabbit polyclonal Cytokeratin 75 antibody raised against the N terminal of KRT75 |
Cytokeratin 75 antibody |
|
70R-3039 |
Fitzgerald |
50 ug |
EUR 467 |
|
Description: Rabbit polyclonal Cytokeratin 75 antibody raised against the middle region of KRT75 |
Cytokeratin 8 antibody |
|
70R-13833 |
Fitzgerald |
100 ug |
EUR 322 |
|
Description: Affinity purified Rabbit polyclonal Cytokeratin 8 antibody |
Cytokeratin 19 antibody |
|
70R-13877 |
Fitzgerald |
100 ug |
EUR 322 |
|
Description: Affinity purified Rabbit polyclonal Cytokeratin 19 antibody |
Cytokeratin 18 antibody |
|
70R-1405 |
Fitzgerald |
100 ug |
EUR 377 |
|
Description: Rabbit polyclonal Cytokeratin 18 antibody raised against the C terminal of KRT18 |
Cytokeratin 18 antibody |
|
70R-1474 |
Fitzgerald |
100 ug |
EUR 377 |
|
Description: Rabbit polyclonal Cytokeratin 18 antibody raised against the N terminal of KRT18 |
Cytokeratin 7 antibody |
|
10R-1826 |
Fitzgerald |
100 ul |
EUR 403 |
|
Description: Mouse monoclonal CK7 antibody |
 pan Cytokeratin antibody |
|
10R-2060 |
Fitzgerald |
100 ul |
EUR 403 |
|
Description: Mouse monoclonal pan Cytokeratin antibody |
 Cytokeratin Pan antibody |
|
10R-2096 |
Fitzgerald |
100 ul |
EUR 403 |
|
Description: Mouse monoclonal Cytokeratin Pan antibody |
Cytokeratin 8 antibody |
|
10R-2766 |
Fitzgerald |
100 ul |
EUR 370 |
|
Description: Mouse monoclonal Cytokeratin 8 antibody |
Cytokeratin 20 antibody |
|
10R-C164a |
Fitzgerald |
50 ug |
EUR 575 |
|
Description: Mouse monoclonal Cytokeratin 20 antibody |
Cytokeratin 20 antibody |
|
10R-C164b |
Fitzgerald |
50 ug |
EUR 624 |
|
Description: Mouse monoclonal Cytokeratin 20 antibody |
Cytokeratin 20 antibody |
|
10R-C164c |
Fitzgerald |
50 ug |
EUR 1011 |
|
Description: Mouse monoclonal Cytokeratin 20 antibody |
 Cytokeratin 2e antibody |
|
10R-C166a |
Fitzgerald |
1 mL |
EUR 269 |
|
Description: Mouse monoclonal Cytokeratin 2e antibody |
 Cytokeratin 4 antibody |
|
10R-C169a |
Fitzgerald |
1 ml |
EUR 537 |
|
Description: Mouse monoclonal Cytokeratin 4 antibody |
 Cytokeratin 6 antibody |
|
10R-C172a |
Fitzgerald |
50 ug |
EUR 445 |
|
Description: Mouse monoclonal Cytokeratin 6 antibody |
Cytokeratin 6 antibody |
|
10R-C172b |
Fitzgerald |
5 mL |
EUR 285 |
|
Description: Mouse monoclonal Cytokeratin 6 antibody |
Cytokeratin 7 antibody |
|
10R-C174a |
Fitzgerald |
50 ug |
EUR 445 |
|
Description: Mouse monoclonal Cytokeratin 7 antibody |
Cytokeratin 8 antibody |
|
10R-C177a |
Fitzgerald |
5 mL |
EUR 346 |
|
Description: Mouse monoclonal Cytokeratin 8 antibody |
Cytokeratin 8 antibody |
|
10R-C177ax |
Fitzgerald |
50 ug |
EUR 493 |
|
Description: Mouse monoclonal Cytokeratin 8 antibody |
Cytokeratin 2 antibody |
|
10R-C179a |
Fitzgerald |
50 ug |
EUR 445 |
|
Description: Mouse monoclonal Cytokeratin 2 antibody |
 Cytokeratin 9 antibody |
|
10R-C196A |
Fitzgerald |
1 mL |
EUR 459 |
|
Description: Mouse monoclonal Cytokeratin 9 antibody |
Cytokeratin 19 antibody |
|
10-1210 |
Fitzgerald |
500 ug |
EUR 435 |
|
Description: Mouse monoclonal Cytokeratin 19 antibody |
Cytokeratin 19 antibody |
|
10R-6759 |
Fitzgerald |
1 ml |
EUR 402 |
|
Description: Mouse monoclonal Cytokeratin 19 antibody |
Cytokeratin 18 antibody |
|
10R-6766 |
Fitzgerald |
1 ml |
EUR 402 |
|
Description: Mouse monoclonal Cytokeratin 18 antibody |
 Cytokeratin AE1 antibody |
|
10R-6767 |
Fitzgerald |
1 ml |
EUR 424 |
|
Description: Mouse monoclonal Cytokeratin AE1 antibody |
 Cytokeratin AE3 antibody |
|
10R-6768 |
Fitzgerald |
1 ml |
EUR 411 |
|
Description: Mouse monoclonal Cytokeratin AE3 antibody |
 Cytokeratin antibody cocktail |
|
10R-6769 |
Fitzgerald |
1 ml |
EUR 560 |
|
Description: Mouse monoclonal Cytokeratin antibody cocktail |
The bulk (23/31; 74%) of the most important immunoreactive proteins recognized had been small (≤250 aa), and 20/31 (65%) had been predicted to be secreted effectors. Not like the robust linear antibody epitopes beforehand recognized in TRP and OMP orthologs, there have been contrasting variations within the E. ch. and E. ca. antigenic repertoires, epitopes and ortholog immunoreactivity. This examine reveals quite a few beforehand undefined immunodominant and subdominant antigens, and illustrates the breadth, complexity, and variety of immunoreactive proteins/epitopes in Ehrlichia.
